Subarachnoid hemorrhage (SAH) is a severe subtype of stroke associated with significant morbidity and mortality. In 85% of people who experience nontraumatic SAH, a ruptured intracranial aneurysm is the underlying cause. Cerebral vasospasm is the narrowing of intracranial arteries, which can lead to hypoperfusion, delayed ischemic deficits, and stroke. Vasospasm continues to be a major complication of SAH and a source of morbidity owing to poorly understood mechanisms and limited treatment options. Survival after aneurysmal subarachnoid hemorrhage (aSAH) has increased in the last few decades, mostly due to early aneurysm repair, vasospasm-prevention treatments, and advances in diagnostic and treatment strategies. Nevertheless, survivors commonly have cognitive impairment that affects their quality of life and functional capacity.

Aneurysmal Subarachnoid Hemorrhage

Epidemiology

Aneurysmal subarachnoid stroke (aSAH) is associated with high mortality, morbidity, and disease burden on health care.1 Accounting for 5% of strokes, aSAH has a peak incidence during the 6th and 7th decades of life. In a large prospective registry, incidence in women was 60% greater than in men (rate ratio: 1.6, 95% CI: 1.3-2).2 Intracranial saccular aneurysms are relatively common, occurring in 1% to 2% of the population.3 A large observational study in Europe and China reported a 28-day case fatality rate of 42%.4 The risk for permanent disability is high, with disability and dependency occurring in close to 50% of survivors. Outcomes correlate with the person’s level of consciousness at presentation, age, blood distribution on images, and the presence of vasospasm or cardiopulmonary complications. Early aggressive treatment and optimal medical and surgical management for complications in experienced centers is paramount to improve outcomes.5

Clinical Presentation

The classic initial symptom with aSAH is a severe thunderclap headache that is maximal at onset and dissimilar to previous headaches but can be preceded by a warning “sentinel headache” in up to 40% of individuals with aSAH.6 Associated factors include physical or psychologic stress; however, aSAH occurs more commonly during activities of daily living with a higher incidence during daily routines that include the Valsalva maneuver (eg, sneezing, defecation).7 A study showed that 50% of aSAH occurred during sleep or rest, but 19% occurred during or within 2 hours of moderate-to-heavy exercise (odds ratio [OR]: 2.7, 95% CI: 1.6-4.6).8 Other symptoms include nausea and/or vomiting, photophobia, and focal neurologic deficits. Severely affected persons can present with profound coma, and the degree of encephalopathy at presentation is a major determinant of the prognosis.9

Diagnosis

Tools for diagnosing aSAH include MR angiography (MRA), CT angiography (CTA), and digital subtraction angiography (DSA). Noncontrast head CT head has sensitivity approaching 100% that drops with time and is approximately 98% at 6 hours if the scan is evaluated by an experienced physician.10 Historically, if head CT results are negative, a lumbar puncture has been performed to rule out SAH in the emergency setting. Meta-analysis of 7 studies of 813 individuals with normal neurologic examination findings, thunderclap headache, normal head CT, and negative results from cerebrospinal fluid (CSF) analysis found no cases of SAH in at least 3 months of follow-up.11

Delayed Cerebral Ischemia and Cerebral Vasospasm

Delayed cerebral ischemia (DCI) is the subsequent deterioration that occurs after aSAH and is multifactorial in etiology, including combined effects of cerebral and microvascular spasm, thrombosis, cortical spreading depolarization, and cerebral autoregulation failure.12,13 Although cerebral vasospasm and DCI may complicate traumatic SAH or ruptured vascular malformations, the most common occurrence is in conjunction with aSAH.14

Pathophysiology and Biomarkers

Along with impaired cerebral autoregulation, vasospasm contributes to decreased cerebral blood flow and delayed ischemia that typically occurs 4 to 14 days after aSAH, with a peak incidence between 6 and 10 days. Angiographic vasospasm occurs in approximately 60% to 70% of people who experience aSAH, and although only 40% of these people develop clinical symptoms, up to 20% will die or have severe deficits.15

Recent research implicates different pathogenic mechanisms including inflammatory pathways, alternations in CSF metal ion concentrations, cholesterol levels, and nitric oxide synthase (NOS) activity. Red blood cell lysis in the subarachnoid spaces releases hemoglobin that causes an immune response triggered by inflammatory cells including neutrophils and macrophages that enter the subarachnoid space. Within 2 to 4 days, this causes endothelin and oxygen free radical release that also plays a role in inflammation and cerebral vasoconstriction.16

Although arterial narrowing has been considered a main mechanism of DCI, treatments to restore luminal patency alone have not resulted in improved clinical outcomes and in a study, 27% of individuals with DCI did not have arterial narrowing.17-19

Risk Factors and Prediction of Vasospasm

Clot volume after SAH is among the most important risk factors to predict vasospasm. The modified Fisher scale grades the degree and extent of SAH on noncontrast head CT at initial presentation and predicts strongly the likelihood of developing vasospasm.20 Advanced age, smoking, alcohol intake, diabetes mellitus or hyperglycemia, preexisting hypertension, and poor neurologic grade at initial presentation also correlate with development of vasospasm.21,22

Medical Treatment

Triple-H Therapy. The use of hypertension, hypervolemia, and hemodilution was first introduced in the 1970s and remains widely used with the intent of increasing cerebral perfusion pressure, blood volume, and cardiac output while optimizing blood viscosity. Although triple-H therapy can be effective in reversing vasospasm, it carries risks including cardiac failure, electrolyte abnormalities, cerebral edema and bleeding diathesis from dilution of clotting factors, and benefit as a prophylactic therapy is questionable.15 In a retrospective study of 45 people, during 55 periods of moderate hypertension, an observable increment in brain oxygenation was seen in 90% of hypertension intervals; and 3 individuals had complications (8%). More aggressive hypervolemic blood pressure augmentation increased the brain oxygenation during 6 of the intervals (60%), with complications in 5 people (50%).23 In a randomized prospective study of 82 participants assigned to receive isotonic crystalloid or 5% albumin solution every 2 hours to maintain normal or elevated cardiac filling pressures (normovolemic vs hypervolemic), there was no difference in mean global cerebral blood flow (CBF) or minimum regional CBF between the 2 treatment groups. Symptomatic vasospasm occurred in 20% of the people in each group.24 Current American Heart Association (AHA)/American Stroke Association (ASA) guidelines recommend maintaining euvolemia and normal circulating blood volume to prevent DCI (Class I; Level of Evidence B).25

Calcium Channel Blockers. Nimodipine is a dihydropyridine calcium channel blocker. In a prospective randomized study with placebo (n = 276) or nimodipine 60 mg (n = 278) given orally every 4 hours for 21 days, the incidence of cerebral infarction was 22% (61/278) for those treated with nimodipine compared with 33% of those given placebo (92/276), with a relative reduction of 34% (95% CI: 13-50; P = .003). Nimodipine significantly reduced the incidence of poor outcomes (death, vegetative state, severe disability) by 40% (P < .001).26 The AHA/ASA guideline recommends nimodipine treatment for all persons who experienced an aSAH. (Class I; Level of Evidence A).25

Other Medications. Because endothelial injury and inflammation may play a role in development of DCI, steroids have been considered, and a randomized controlled trial of methylprednisolone in 97 participants with a diagnosis of aSAH did not reduce the incidence of symptomatic vasospasm but did improve functional outcome at 1 year.27

Meta-analysis of 6 randomized trials showed a lower incidence of DCI and mortality in those participants who were also treated with statins, but randomized clinical trials have not shown any benefit of statin treatment (40 or 80 mg for 21 days) on decreasing incidence of DCI or on short- or long-term outcomes of people with DCI.28-30 Similarly, although magnesium is known to be a well-tolerated neuroprotectant, no benefit on outcomes with magnesium treatment has been seen.31-33 A meta-analysis demonstrated that prophylactic intravenous magnesium sulfate decreased incidence of DCI but did not increase the probability of good neurologic outcome for persons with aSAH.34

Endovascular Treatments for Cerebral Vasospasm

Balloon Angioplasty. A mechanical means of re-expanding an intracranial vessel, balloon angioplasty is thought to inflict a paralytic injury on smooth muscle cells that prevents subsequent vasoconstriction.35 Although it is highly successful at restoring luminal diameter, there are several limitations. First, balloon angioplasty can only be done on larger, more proximal vessels and so does not address microcirculatory processes thought to be the primary pathology associated with DCI. Balloon angioplasty is also the most invasive treatment with the highest risk, and complications include vessel perforation, arterial dissection, ischemic stroke, and hemorrhagic transformation of infarcted tissue.36 In a study comparing the effectiveness of balloon angioplasty to intra-arterial nimodipine for refractory vasospasm, both therapies were effective for achieving radiographic resolution of vasospasm.37 An evaluation of prophylactic balloon angioplasty in 85 people with Fisher grade 3 SAH significantly decreased the need for urgent rescue therapy for symptomatic vasospasm (12 vs 26%, P = .03) but no statistical difference in the rate of cerebral infarction or poor outcome at 3 months.38

Intra-arterial Vasodilators. Calcium channel blockers (nimodipine, nicardipine, verapamil) and phosphodiesterase inhibitors (papaverine, milrinone) are among the intra-arterial vasodilators used for endovascular treatment of vasospasm. These treatments are generally low risk; however, complications can occur including intra-cranial hypertension, systemic hypotension, and seizures.

A recent comprehensive meta-analysis included 55 studies (1,571 participants) to evaluate the effect of intra-arterial vasodilators in vasospasm treatment showed a robust immediate angiographic response (almost 90%) with postprocedure neurologic improvement of just less than 60%. Of the studies that provided information on clinical outcome in 1,111 people, 66% had overall a good clinical outcome. When whose who were selected for intra-arterial vasodilation based on findings of transcranial Doppler ultrasound (TCD), the rate of a good outcome increased to 72% and the adjusted mortality estimate was 5%. Intra-arterial fasudil showed the highest rates of angiographic response at 99% with good clinical outcome and lowest mortality.39 In another meta-analysis of 1,154 individuals, nicardipine infusion reduced the risk of poor outcome and mortality after aSAH.40 Another study enrolled 29 participants; intra-arterial nimodipine led to vasodilation in angiography and improvement in clinical symptoms.41

Investigational Treatments

Intrathecal drug administration for treatment of vasospasm may be effective because it delivers a higher drug concentration with minimal side effects. Calcium channel blockers (eg, nicardipine) via an external ventricular drain have had positive results in both preventing and treating vasospasm, but further studies are warranted.42,43 In another study, stent retriever use resulted in cerebral vasodilation and reversal of focal neurologic deficits with a longer lasting effect.44 Continuous low-dose unfractionated heparin infusion is being studied in the ASTROHa trial.

Conclusion

Despite advances in aneurysm treatments, cerebral vasospasm remains a contributor to morbidity and mortality in aSAH. The pathogenesis of vasospasm and DCI is likely multifactorial and includes angiographic vasospasm, cortical spreading depression, microthrombosis, and microcirculatory restrictions. Although a number of pharmacologic treatments and endovascular interventions are available, nimodipine remains the only adjunctive treatment demonstrated to improve clinical outcomes in randomized controlled trials.

1. Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. Lancet. 2017;389(10069):655-666.

2. Epidemiology of aneurysmal subarachnoid hemorrhage in Australia and New Zealand: incidence and case fatality from the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). Stroke. 2000;31(8):1843-1850.

3. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78(12):1365-1372.

4. Ingall T, Asplund K, Mahonen M, Bonita R. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. Stroke. 2000;31(5):1054-1061.

5. le Roux AA, Wallace MC. Outcome and cost of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am. 2010;21(2):235-246.

6. Bassi P, Bandera R, Loiero M, Tognoni G, Mangoni A. Warning signs in subarachnoid hemorrhage: a cooperative study. Acta Neurol Scand. 1991;84(4):277-281.

7. Anderson C, Ni Mhurchu C, Scott D, et al. Triggers of subarachnoid hemorrhage: role of physical exertion, smoking, and alcohol in the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). Stroke. 2003;34(7):1771-1776.

8. Vlak MH, Rinkel GJ, Greebe P, Algra A. Risk of rupture of an intracranial aneurysm based on patient characteristics: a case-control study. Stroke. 2013;44(5):1256-1259.

9. Lawton MT, Vates GE. Subarachnoid hemorrhage. N Engl J Med. 2017;377(3):257-266.

10. Cohen-Gadol AA, Bohnstedt BN. Recognition and evaluation of nontraumatic subarachnoid hemorrhage and ruptured cerebral aneurysm. Am Fam Physician. 2013;88(7):451-456.

11. Savitz SI, Levitan EB, Wears R, Edlow JA. Pooled analysis of patients with thunderclap headache evaluated by CT and LP: is angiography necessary in patients with negative evaluations? J Neurol Sci. 2009;276(1-2):123-125.

12. Rowland MJ, Hadjipavlou G, Kelly M, Westbrook J, Pattinson KT. Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm. Br J Anaesth. 2012;109(3):315-329.

13. Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10(1):44-58.

14. Izzy S, Muehlschlegel S. Cerebral vasospasm after aneurysmal subarachnoid hemorrhage and traumatic brain injury. Curr Treat Options Neurol. 2014;16(1):278.

15. Dabus G, Nogueira RG. Current options for the management of aneurysmal subarachnoid hemorrhage-induced cerebral vasospasm: a comprehensive review of the literature. Interv Neurol. 2013;2(1):30-51.

16. Rodriguez-Rodriguez A, Egea-Guerrero JJ, et al. Biomarkers of vasospasm development and outcome in aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2014;341(1-2):119-127.

17. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015-3021.

18. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618-625.

19. Wagner M, Steinbeis P, Guresir E, et al. Beyond delayed cerebral vasospasm: infarct patterns in patients with subarachnoid hemorrhage. Clin Neuroradiol. 2013;23(2):87-95.

20. Friedman JA, Goerss SJ, Meyer FB, et al. Volumetric quantification of Fisher Grade 3 aneurysmal subarachnoid hemorrhage: a novel method to predict symptomatic vasospasm on admission computerized tomography scans. J Neurosurg. 2002;97(2):401-407.

21. Inagawa T, Yahara K, Ohbayashi N. Risk factors associated with cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo). 2014;54(6):465-473.

22. de Rooij NK, Rinkel GJ, Dankbaar JW, Frijns CJ. Delayed cerebral ischemia after subarachnoid hemorrhage: a systematic review of clinical, laboratory, and radiological predictors. Stroke. 2013;44(1):43-54.

23. Raabe A, Beck J, Keller M, Vatter H, et al. Relative importance of hypertension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 2005;103(6):974-981.

24. Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31(2):383-391.

25. Connolly ES, Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737.

26. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636-642

27. Gomis P, Graftieaux JP, Sercombe R, et al. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2010;112(3):681-688.

28. Kirkpatrick PJ, Turner CL, Smith C, et al. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol. 2014;13(7):666-675.

29. Wong GK, Chan DY, Siu DY, et al. High-dose simvastatin for aneurysmal subarachnoid hemorrhage: multicenter randomized controlled double-blinded clinical trial. Stroke. 2015;46(2):382-388.

30. Su SH, Xu W, Hai J, Wu YF, Yu F. Effects of statins-use for patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Sci Rep. 2014;4:4573.

31. Lingam I, Robertson NJ. Magnesium as a neuroprotective agent: a review of Its use in the fetus, term infant with neonatal encephalopathy, and the adult stroke patient. Dev Neurosci. 2018;40(1):1-12.

32. Wong GK, Poon WS, Chan MT, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke. 2010;41(5):921-926.

33. Dorhout Mees SM, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012;380(9836):44-49.

34. Golan E, Vasquez DN, Ferguson ND, Adhikari NK, Scales DC. Prophylactic magnesium for improving neurologic outcome after aneurysmal subarachnoid hemorrhage: systematic review and meta-analysis. J Crit Care. 2013;28(2):173-181.

35. Abruzzo T, Moran C, Blackham KA, et al. Invasive interventional management of post-hemorrhagic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurointerv Surg. 2012;4(3):169-177.

36. Findlay JM, Nisar J, Darsaut T. Cerebral vasospasm: a review. Can J Neurol Sci. 2016;43(1):15-44.

37. Aburto-Murrieta Y, Marquez-Romero JM, Bonifacio-Delgadillo D, Lopez I, Hernandez-Curiel B. Endovascular treatment: balloon angioplasty versus nimodipine intra-arterial for medically refractory cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Vasc Endovascular Surg. 2012;46(6):460-465.

38. Zwienenberg-Lee M, Hartman J, Rudisill N, et al. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke. 2008;39(6):1759-1765.

39. Venkatraman A, Khawaja AM, Gupta S, et al. Intra-arterial vasodilators for vasospasm following aneurysmal subarachnoid hemorrhage: a meta-analysis. J Neurointerv Surg. 2018;10(4):380-387.

40. Huang RQ, Jiang FG, Feng ZM, Wang TY. Nicardipine in the treatment of aneurysmal subarachnoid haemorrhage: a meta-analysis of published data. Acta Neurol Belg. 2013;113(1):3-6.

41. Kim SS, Park DH, Lim DJ, et al. Angiographic features and clinical outcomes of intra-arterial nimodipine injection in patients with subarachnoid hemorrhage-induced vasospasm. J Korean Neurosurg Soc. 2012;52(3):172-178.

42. Goodson K, Lapointe M, Monroe T, Chalela JA. Intraventricular nicardipine for refractory cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care. 2008;8(2):247-252.

43. Stuart D, Christian R, Uschmann H, Palokas M. Effectiveness of intrathecal nicardipine on cerebral vasospasm in non-traumatic subarachnoid hemorrhage: a systematic review. JBI Database System Rev Implement Rep. 2018;16(10):2013-2026.

44. Bhogal P, Loh Y, Brouwer P, Andersson T, Soderman M. Treatment of cerebral vasospasm with self-expandable retrievable stents: proof of concept. J Neurointerv Surg. 2017;9(1):52-59.